These preliminary findings suggest that stimulation of the subthalamic nucleus may reduce the symptoms of severe forms of OCD but is associated with a substantial risk of serious adverse events. (ClinicalTrials.gov number, NCT00169377.)
Focal cortical dysplasia (FCD) is an increasingly recognized cause of intractable epilepsy. Surgical data suggest that the dysplastic cortex should be removed to obtain freedom from seizures, but the prognosis remains poor as FCD is difficult to delineate by imaging. We retrospectively analysed a series of 28 patients (aged 5-41 years, median 16.5 years) with FCD who had been investigated by stereoelectroencephalography (SEEG) between 1964 and 1995. Neurophysiological data were correlated with histological findings and surgical outcome. MRI was available for only seven patients. Severe partial epilepsy of early onset, pre-existing neurological deficit (68%) and cognitive impairment were the main clinical features. FCD was distributed equally between all lobes except for the temporal lobe, and was found predominantly on the mesial aspect of the cerebral hemispheres. SEEG findings provided evidence of dysplastic tissue epileptogenicity, as demonstrated by intralesional rhythmic spike discharges, the onset of ictal discharges and a low epileptogenic threshold. The epileptogenic zone corresponded to histologically defined FCD in 82% of the cases. Despite the lack of adequate neuroimaging in most cases, 64% of the patients became seizure-free after surgery. The main predictors of a favourable outcome were complete removal of the epileptogenic zone (P< 0.01) and complete removal of the dysplastic cortex (P< 0.01). These results emphasize the usefulness of neurophysiological data in accurately assessing the extent of the FCD.
Diffuse low-grade gliomas are highly epileptogenic brain tumours. We aimed to explore the natural course of epileptic seizures, their predictors and the prognostic significance of their occurrence in adult patients harbouring a diffuse low-grade glioma. An observational retrospective multicentre study examined 1509 patients with diffuse low-grade gliomas to identify mutual interactions between tumour characteristics, tumour course and epileptic seizures. At diagnosis, 89.9% of patients had epileptic seizures. Male gender (P = 0.003) and tumour location within functional areas (P = 0.001) were independent predictors of a history of epileptic seizures at diagnosis. Tumour volume, growth velocity, cortical location, histopathological subtype or molecular markers did not significantly affect epileptic seizure occurrence probability. Prolonged history of epileptic seizures (P < 0.001), insular location (P = 0.003) and tumour location close to functional areas (P = 0.038) were independent predictors of uncontrolled epileptic seizures at diagnosis. Occurrence of epileptic seizures (P < 0.001), parietal (P = 0.029) and insular (P = 0.002) locations were independent predictors of uncontrolled epileptic seizures after oncological treatment. Patient age (P < 0.001), subtotal (P = 0.007) and total (P < 0.001) resections were independent predictors of total epileptic seizure control after oncological treatment. History of epileptic seizures at diagnosis and total surgical resection were independently associated with increased malignant progression-free (P < 0.001 and P < 0.001) and overall (P < 0.001 and P = 0.016) survivals. Epileptic seizures are independently associated with diffuse low-grade glioma prognosis. Patients diagnosed with epileptic seizures and those with complete and early surgical resections have better oncological outcomes. Early and maximal surgical resection is thus required for diffuse low-grade gliomas, both for oncological and epileptological purposes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.